A PD Solution to Protect Peritoneal Membranes
PD-protec® by Zytoprotec, which now has FDA orphan drug status, is in Phase III trials among 300 patients in the US and Europe. The product aims to reduce PD complications such as peritonitis and membrane failure.
Read the full article » | Posted 01-11-2018
Related Articles
- Byonyks’ X1 APD Cycler Received FDA 510(k) Approval Last Summer Posted 02-17-2026
- FDA granted 510(k) approval to Outset for Next generation Tablo with Cybersecurity Posted 02-17-2026
- Drs. Monica Farcus and Jeffrey Perl Win the Mitchell Award for Health System Innovation Posted 01-16-2026
- Nephrodite Wins FDA Breakthrough Device Designation for “Holly” Posted 01-16-2026